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Abstract 
 
Macrophage polarization refers to the ability of these cells to adopt different functional phenotypes 
according to their environment. Mitogen-activated protein kinase phosphatase-1 (MKP-1) is known 
to regulate the classical lipopolysaccharide (LPS) -induced proinflammatory macrophage activation 
and the inflammatory response. Here we investigated the effects of MKP-1 on the anti-inflammatory 
and healing-promoting macrophage phenotype induced by cytokines IL-4 and IL-13 and examined 
the potential mediator role of MKP-1 in glucocorticoid effects on the two macrophage phenotypes. 
  
In MKP-1-deficient macrophages treated with IL-4 and IL-13 to induce the anti-inflammatory 
phenotype, the expression of phenotypic markers arginase 1, Ym-1 and FGF2 was reduced as 
compared to wild-type cells. In contrast, LPS-induced expression of the proinflammatory factors  
IL-6 and iNOS was significantly higher in MKP-1 deficient macrophages. Dexamethasone 
suppressed the proinflammatory phenotype and enhanced the anti-inflammatory phenotype. 
Interestingly, both of these glucocorticoid effects were attenuated in macrophages from MKP-1 
deficient mice. Accordingly, dexamethasone increased MKP-1 expression in both LPS- and IL4+13-
treated wild-type cells. 
 
In conclusion, the findings support MKP-1 as an endogenous mechanism able to shift macrophage 
activation from the classical proinflammatory state towards the anti-inflammatory and healing-
promoting phenotype. In addition, MKP-1 was found to mediate the anti-inflammatory effects of 
dexamethasone in a dualistic manner: by suppressing the proinflammatory macrophage activation 
and by enhancing the healing-promoting macrophage phenotype. 
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Introduction 
Macrophages are important immune effector cells responsible for several physiological functions 
related to homeostasis and immunity [1]. They clear cellular debris and participate in recycling of 
nutrients (e.g. iron) [2,3]. In infections, macrophages phagocytize pathogens and present antigens to 
lymphocytes [4]. They also regulate inflammation by secreting pro-inflammatory and anti-
inflammatory cytokines and other soluble factors. It is nowadays accepted that the macrophages 
performing different tasks actually display distinct phenotypes [5,6], a phenomenon known as 
macrophage polarization. 
 
Macrophage phenotypes were initially modeled after the Th1/Th2 paradigm for T lymphocytes. This 
scheme has “classically activated” or M1 macrophages, induced by microbial products and 
proinflammatory stimuli, on one end. On the other end are macrophages that do not promote immune 
responses but support resolution of inflammation and tissue healing. These cells are collectively 
called “alternatively activated” or M2 macrophages and are often subdivided according to the 
phenotype-inducing stimulus and / or supposed function related to the phenotype. More recently, it 
has been increasingly recognized that grouping such diverse cells into two predetermined categories 
is not optimal; the characteristic set of features caused by each “polarizing” factor have been 
recommended to be considered as a distinct phenotype, especially concerning alternatively activated 
macrophages [7]. 
 
The macrophage phenotype induced by activators of toll-like receptor 4 (TLR4), such as bacterial 
lipopolysaccharide (LPS), along with that induced by the proinflammatory cytokine interferon 
gamma (INFγ), is a well-characterized form of “classical macrophage activation”. These cells 
promote inflammation and effectively destroy intracellular pathogens in a setting of infection [8]. 
They express inducible nitric oxide synthase (iNOS), which converts L-arginine into L-citrulline 
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simultaneously releasing nitric oxide (NO), a potent vasodilator and cytotoxic effector molecule. 
Other characteristic inflammatory factors produced by classically activated macrophages include 
interleukin 6 (IL-6) and tumor necrosis factor (TNF) [9]. While these cells play a critical role in 
controlling infection, excessive or dysregulated classical activation has been implicated in the 
development of autoimmune and degenerative diseases [2] as well as atherosclerosis [10], obesity 
and insulin resistance [11]. 
 
A relatively well-established example of “alternative macrophage activation” is the phenotype 
induced by the major Th2 cytokines IL-4 and IL-13. These IL-4 / IL-13 -activated macrophages are 
associated with phagocytosis of tissue debris, as well as with the resolution of inflammation and 
wound healing [12], and are characterized by upregulation of factors involved in fibroblast activation 
and extracellular matrix synthesis, such as Ym-1, arginase 1 and fibroblast growth factor 2 (FGF2) 
[13,14]. While proinflammatory macrophages produce NO from arginine, macrophages activated by 
IL-4 and IL-13 express arginase 1 at high levels. This enzyme converts L-arginine into L-ornithine, 
which in turn acts as a precursor of many extracellular matrix components supporting wound healing 
[15,16]. Macrophage activation by IL-4 and IL-13 is critical in the resolution of inflammation and 
wound healing, but excessive and / or dysregulated forms of it have been linked to aberrant fibroblast 
activation and pathogenesis of fibrotic diseases. Accordingly, macrophages displaying an alternative 
phenotype stimulated by IL-4 and IL-13 have been detected in fibrotic lungs [17], kidneys [18] and 
liver [15]. 
 
Mitogen activated protein kinase phosphatases (MKPs), also known as dual specificity phosphatases 
(DUSPs), are enzymes that dephosphorylate mitogen activated protein kinases (MAKPs) and thus 
inactivate signaling cascades mediated through these pathways [19–21]. MAPKs regulate the activity 
of several enzymes and transcription factors involved in inflammatory responses [22,23]. MKP-1, 
which preferentially dephosphorylates p38 and JNK, is the best known MAPK phosphatase 
5 
 
[20,21,24]. MKP-1 expression is upregulated in response to many extracellular signals and cellular 
stress, such as LPS, cytokines and heat shock [23,25]. MKP-1 deficiency has been associated with an 
enhanced inflammatory response, and increased expression of proinflammatory genes has been 
observed both in macrophages isolated from MKP-1 knockout mice and in cells treated with MKP-1 
targeting siRNAs [26–29]. Accordingly, MKP-1 deficient mice develop more severe disease in 
models of septic shock or collagen-induced arthritis [30,31]. Intriguingly, MKP-1 expression has been 
shown to be increased by certain anti-inflammatory drugs, i.e. glucocorticoids [32–34], the anti-
rheumatic drug aurothiomalate [35] and the PDE4 inhibitor rolipram [36], and this property is thought 
to mediate many of their anti-inflammatory effects. 
 
In contrast to the relatively well-established role of MKP-1 in classical macrophage activation, its 
effects on alternative macrophage activation remain mostly unexplored. The aim of the present study 
was to investigate the regulatory role of MKP-1 in IL-4 and IL-13 -induced alternative macrophage 
activation in comparison to its effects on TLR4 (LPS) -induced classical macrophage activation, and 
to evaluate if MKP-1 has a role in mediating the anti-inflammatory effects of the glucocorticoid 
dexamethasone in macrophages. In the nomenclature we adhere to the recent consensus paper [7] and 
refer to TLR4 activator -induced classically activated proinflammatory macrophage phenotype as 
M(LPS) cells and to IL-4 and IL-13 -induced alternatively activated anti-inflammatory and healing-
promoting phenotype as M(IL-4/IL-13) cells. 
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Materials and methods 
 
Cell cultures and macrophage polarization 
 
Murine J774 macrophages (American Type Culture Collection, Manassas, VA, USA) were cultured 
at 37°C in a 5% CO2 atmosphere in Dulbecco's modified Eagle's medium with Ultraglutamine 1 
(Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 
100 µg/ml streptomycin and 250 ng/ml amphotericin B (Invitrogen Co., Carlsbad, CA, USA) and 
harvested with trypsin-EDTA (Invitrogen Co.). Cells were cultured in 24-well plates for RNA 
extraction, ELISA measurements, and preparation of whole-cell lysates for Western blotting. 
Confluent cultures were exposed to fresh culture medium containing the compounds of interest.  
 
Isolation and culturing of mouse peritoneal macrophages were carried out as described earlier [36]. 
In brief, male C57BL/6 MKP-1(–/–) mice (originally generated by the R. Bravo laboratory at Bristol-
Myers Squibb Pharmaceutical Research Institute [37]) were bred in the University of Tampere School 
of Medicine animal facilities. These mice, along with their wild-type (WT) controls, were housed 
under standard conditions of light (12-12 h light–dark cycle), temperature (22 ± 1°C) and humidity 
(50–60%). Food and water were provided ad libitum. In each experiment, cells from six WT and six 
knockout (KO) mice were pooled to give n=4. 
 
In collection of peritoneal macrophages, the experiments were carried out in accordance with the 
legislation for the protection of animals used for scientific purposes (Directive 2010/63/EU), and the 
study was approved by The National Animal Experiment Board. Mice were sacrificed by suffocation 
with CO2, followed by an immediate cervical dislocation. Primary peritoneal macrophages were 
obtained by intraperitoneal lavage with sterile phosphate-buffered saline (PBS) supplemented with 
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0.2 mM EDTA. Cells were washed, resuspended in RPMI 1640 medium supplemented with 2% heat-
inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 250 ng/ml 
amphotericin B, and seeded on 24-well plates. The cells were incubated overnight and washed with 
medium to remove non-adherent cells before the experiments. 
 
In order to study the type of TLR4 activation -induced classical macrophage activation, the cells were 
incubated with 10 ng/ml (J774) or 100 ng/ml (peritoneal macrophages) of a known activator of TLR4, 
bacterial LPS (Escherichia coli, 0111:B4, product number E-4391, Sigma) for 24  h (J774) or 4  h 
(peritoneal macrophages). This classical phenotype is henceforth called M(LPS). In experiments 
examining alternative activation, a combination of 10 ng/ml of IL-4 and IL-13 (both from R&D 
Systems, Minneapolis, MN, USA) was used to induce an alternative phenotype henceforth called 
M(IL-4/IL-13). When relevant, 1 µM dexamethasone was used in addition to LPS or IL-4 and IL-13. 
The concentrations of the chemical stimuli (LPS and IL-4 + IL-13) were chosen following our 
previous studies and literature, and the time points used in the experiments were selected based on 
time series in J774 murine macrophage studies (see Figs. 1 and 6) and on our preliminary experiments 
with peritoneal macrophages. The dexamethasone concentrations used in the experiments were 
chosen based on our previously published dose-response data [38]. 
 
Cell viability after treatment with the investigated compounds was excluded by modified XTT test 
(Cell Proliferation Kit II, Roche Diagnostics, Mannheim, Germany) according to the manufacturer's 
instructions. 
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Preparation of protein extracts 
 
At predetermined time points, the culture medium was carefully removed and stored at -20°C for later 
analysis. The cells were rapidly washed with ice-cold phosphate-buffered saline and solubilized in 
cold lysis buffer containing 10 mM Tris base, pH 7.4, 5 mM EDTA, 50 mM NaCl, 1% Triton X-100, 
0.5 mM phenylmethylsulphonyl fluoride, 1 mM sodium orthovanadate, 20 μg/ml leupeptin, 50 μg/ml 
aprotinin, 5 mM NaF, 2 mM sodium pyrophosphate and 10 μM n-octyl-β-D-glucopyranoside. After 
incubation on ice for 15 minutes, lysates were centrifuged (12,000 g, 4°C, 10 min), supernatants were 
collected and mixed 3:1 with SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 
0.025% bromophenol blue and 5% β-mercaptoethanol). The samples were stored at -20°C until 
analyzed. An aliquot of the supernatant was used to determine protein concentration using the 
Coomassie blue method [39]. 
 
Western blotting 
 
Prior to Western blotting, samples were boiled for 10 min and 20 μg of protein was loaded per lane 
on 10% or 12% SDS-polyacrylamide gels and separated by electrophoresis. Proteins were transferred 
to Hybond enhanced chemiluminescence nitrocellulose membrane (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK). 
 
After the transfer, the membrane was blocked with TBS/T (20 mM Tris-base pH 7.6, 150 mM NaCl, 
0.1% Tween-20) containing 5% of non-fat dry milk (arginase 1 and β-actin) or 5% bovine serum 
albumin (MKP-1) at room temperature for one hour and incubated with the primary antibody in the 
blocking solution for one hour at room temperature (arginase 1) or at 4°C overnight (MKP-1 and β-
actin). The membrane was washed with TBS/T, incubated with the secondary antibody in the 
blocking solution at room temperature for one hour and washed. Bound antibody was detected using 
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SuperSignal West Pico or Dura chemiluminescent substrate (Pierce, Rockford, IL, USA) and 
ImageQuant LAS 4000 mini imaging system (GE Healthcare). The chemiluminescent signal was 
quantified with ImageQuant TL 7.0 image analysis software. 
 
Rabbit polyclonal arginase 1, MKP-1 and β-actin (loading control) antibodies (primary antibodies), 
and goat HRP-conjugated anti-rabbit polyclonal antibody (secondary antibody) were obtained from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). 
 
ELISA 
 
The concentration of IL-6 in culture media was determined by ELISA, using reagents from R&D 
Systems Europe Ltd., Abingdon, UK (Catalog DY406), adhering to the protocol detailed by the 
manufacturer. The detection limit was 0.3 pg/ml. All samples were assayed in duplicate. 
 
Nitrite measurement with Griess method 
 
Nitric oxide (NO) production was determined by measuring the accumulation of nitrite, a stable 
metabolite of NO in the aqueous environment, into the culture medium by the Griess reaction [40]. 
All samples were assayed in duplicate. 
 
RNA isolation and quantitative RT-PCR 
 
At predetermined time points, culture medium was removed, and total RNA was extracted using 
GenElute™ Mammalian Total RNA Miniprep kit (Sigma-Aldrich Co.). Total RNA (100 ng) was 
reverse-transcribed to cDNA using TaqMan Reverse Transcription reagents and random hexamers 
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(Applied Biosystems, Foster City, CA, USA). cDNA was diluted 1:20 with RNase-free water and 
subjected to quantitative RT-PCR using TaqMan Universal PCR Master Mix and ABI Prism 7000 
sequence detection system (Applied Biosystems). 
 
Primers and probes for murine IL-6, iNOS, MKP-1, arginase 1, Ym-1 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Table 1) were optimized according to the manufacturer's 
instructions in TaqMan Universal PCR Master Mix Protocol part number 4304449 revision C. The 
mRNA levels of basic fibroblast growth factor (FGF2) were determined by using TaqMan® Gene 
Expression Assay Mm00433287_m1 (Applied Biosystems). The PCR reaction parameters were as 
follows: incubation at 50°C for 2 min, incubation at 95°C for 10 min, followed by 40 cycles of 
denaturation at 95°C for 15 s, and annealing and extension at 60°C for 1 min. Each sample was 
assayed in duplicate. The relative mRNA levels were quantified and compared using the relative 
standard curve method as described in Applied Biosystems User Bulletin number 2. For the FGF2 
Gene Expression Assay, the relative mRNA levels were determined with the ∆∆CT method. 
 
Statistics 
 
Results are expressed as mean + standard error of mean (SEM). When indicated, statistical 
significance was calculated by ANOVA followed by Dunnett's or Bonferroni's multiple comparisons 
test where appropriate. Differences were considered significant at p < 0.05. For determining area 
under curve, trapezoidal integration was used. The statistical software GraphPad InStat3 was used for 
the analyses. The study was conducted in accordance with the BCPT policy for experimental and 
clinical studies [41]. 
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Results 
 
Markers of classical M(LPS) phenotype are increased while those of alternative 
M(IL-4/IL-13) phenotype are decreased in macrophages from MKP-1 deficient 
mice 
 
The levels of interleukin 6 (IL-6) and inducible nitric oxide synthase (iNOS) expressions were 
investigated as typical markers of classical M(LPS) activation in J774 macrophages. LPS 
significantly increased the expression of both of these inflammatory factors, with mRNA levels 
peaking at 4-6 h and returning to basal levels at 24 h following exposure to LPS (Figures 1A-B). 
Accordingly, the levels of arginase 1 and Ym-1 were measured as typical markers of alternative  
M(IL-4/IL-13) activation. The combination of IL-4 and IL-13 increased the expression of arginase 1 
and Ym-1 but the effect was rather slow in onset and mRNA levels continued to increase up to  
12-24 h following IL-4/IL-13 stimulation. (Figures 1C-D). 
 
To investigate the role of MKP-1 in classical M(LPS) and alternative M(IL-4/IL-13) macrophage 
activation, peritoneal macrophages were isolated from MKP-1 deficient and wild-type mice. After 
stimulation with LPS, IL-6 expression was 71% and iNOS expression 136% higher in macrophages 
from MKP-1 deficient mice compared to cells from wild-type mice (Figure 2A-B). In contrast, when 
the cells were stimulated with the combination of IL-4 and IL-13 to induce the alternative phenotype, 
the expression of arginase 1, Ym-1 and FGF2 was significantly lower (by 42%, 86% and 37%, 
respectively) in the macrophages from MKP-1 deficient mice than in those from wild-type animals 
(Figure 2C-E). These data suggest that MKP-1 is an endogenous factor regulating macrophage 
polarization from a proinflammatory phenotype towards an anti-inflammatory and tissue healing -
promoting phenotype. 
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The effects of dexamethasone on M(LPS) and M(IL-4/IL-13) markers are 
attenuated in macrophages from MKP-1 deficient mice 
 
Glucocorticoids are known to attenuate classical proinflammatory M(LPS) and to promote alternative 
inflammation-resolving M(IL-4/IL-13) macrophage activation, as also demonstrated here in J774 
macrophages. When dexamethasone was added into the culture, it markedly inhibited IL-6 and iNOS 
mRNA expression (by 69% and 63%, respectively) and IL-6 and nitric oxide production (by 89% and 
95%, respectively) in LPS-treated J774 macrophages (Figure 3). In contrast, dexamethasone 
increased the expression of arginase 1 (mRNA by 85%, protein by 71%) and Ym-1 (by 1630%) in 
macrophages exposed to the combination of IL-4 and IL-13 (Figure 4). 
 
To study the role of MKP-1 in those glucocorticoid effects, we investigated the effects of 
dexamethasone in peritoneal macrophages from MKP-1 deficient and wild-type mice. As shown in 
Figures 5A and 5B, dexamethasone downregulated IL-6 and iNOS expression in both wild-type and 
MKP-1 deficient peritoneal macrophages exposed to LPS, but the effect in macrophages from  
MKP-1 deficient mice was attenuated in a statistically significant manner. In contrast, dexamethasone 
enhanced the expression of the M(IL-4/IL-13) markers arginase 1, Ym-1 and FGF2 in peritoneal 
macrophages from wild-type animals. Intriguingly, the effect of dexamethasone on the  
M(IL-4/IL-13) markers was significantly attenuated in macrophages from MKP-1 deficient mice 
(Figures 5C-E). These data suggest that MKP-1 mediates the anti-inflammatory effects of 
glucocorticoids via two mechanisms: by suppressing proinflammatory macrophage activation and 
promoting anti-inflammatory macrophage phenotype. 
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Dexamethasone enhances MKP-1 expression in murine macrophages 
 
To support the role of MKP-1 in the observed glucocorticoid effects, we studied the effects of 
dexamethasone on MKP-1 expression. In the resting state, peritoneal macrophages from wild-type 
mice expressed MKP-1 at low levels. When dexamethasone was introduced to the culture, it increased 
MKP-1 expression up to five-fold. The MKP-1 increasing effect of dexamethasone was duplicated 
when it was added in combination with LPS or IL-4 and IL-13. (Figure 6A)  
 
Similar effects were observed in J774 cells (Figures 6B-D). The time-course of MKP-1 expression in 
J774 macrophages (Figure 6B) showed a rapid increase which peaked at 1 h and was followed by 
another peak at 4 h possibly induced by pro-inflammatory cytokines trigged by LPS stimulation or 
feedback loops between MKP-1 and p38 kinase [42,43]. Dexamethasone enhanced MKP-1 
expression in unstimulated J774 cells as well as in those exposed to LPS or IL-4 + IL-13, the 
combination of LPS and dexamethasone being able to induce the highest increase. The effects seen 
at mRNA level were also translated to protein levels (Figure 6D). 
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Discussion 
In the present study, we show that both classical M(LPS) and alternative M(IL-4/IL-13) macrophage 
activation are significantly altered in cells from MKP-1 deficient mice. Opposite directions in the 
changes were observed: M(IL-4/IL-13) activation was attenuated whereas M(LPS) activation was 
augmented in macrophages from MKP-1 deficient animals. These findings display a central role of 
MKP-1 in the regulation of macrophage polarization towards the M(IL-4/IL-13) phenotype, which is 
critical in the resolution of inflammation and wound healing. More interestingly, the anti-
inflammatory steroid dexamethasone was found to suppress M(LPS) activation and to enhance  
M(IL-4/IL-13) activation, and both of these effects were attenuated in cells from MKP-1 deficient 
animals. These findings together imply that MKP-1 is a significant mechanism in limiting 
inflammation and promoting tissue healing, and as such, can be considered a promising anti-
inflammatory drug target. 
 
The effects of MKP-1 on proinflammatory states, corresponding to M(LPS) activation, have been 
studied previously [21–23]. MKP-1 has been shown to be upregulated, possibly as a regulatory 
feedback mechanism, by pro-inflammatory stimuli such as IL-1 and bacterial LPS [26–29], and this 
was also confirmed in the present study. In addition, we found that the expression levels of M(LPS) 
markers iNOS and IL-6 were increased in macrophages from MKP-1 deficient mice as compared to 
cells from wild-type animals. These findings are supported by previous studies [28–30]. In animal 
models, MKP-1 deficiency has been shown to increase lethality in experimentally induced sepsis and 
endotoxic shock [30,41], as well as to cause increased inflammation and osteolysis in experimental 
arthritis and periodontitis [31,42]. Together these findings support the view that MKP-1 is a part of 
an endogenous feedback loop to control and limit inflammation mediated by proinflammatory 
classically activated macrophages [21,26]. 
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In contrast to the well-established suppressive effects of MKP-1 on M(LPS) activation, very little is 
known about its possible effects on M(IL-4/IL-13) and other alternatively activated macrophage 
phenotypes. In connection to their studies on MKP-1 and macrophages in atherosclerosis, Kim and 
coworkers recently reported that  MKP-1 deficiency suppressed IL-4-induced conversion of 
macrophages towards the M2 phenotype [43]. Our results corroborate these findings and extend them 
by showing that the enhancing effect of dexamethasone on M(IL-4/IL-13) activation is also mediated 
by MKP-1. Taken together, in primary peritoneal macrophages from MKP-1-deficient animals, the 
expression of the markers of inflammation-resolving M(IL-4/IL-13) phenotype in response to the 
respective stimuli was significantly attenuated, along with the increased expression of markers of the 
proinflammatory M(LPS) phenotype in response to the respective factor. These findings are plausible 
evidence that MKP-1 regulates the balance in functional macrophage phenotypes and indicate that 
MKP-1 shifts macrophage polarization towards an inflammation-alleviating phenotype. MKP-1 has 
also been shown to regulate the metabolic aspects of macrophage phenotype [43], factors that the 
present study was unable to address. Investigating these factors further is a promising avenue of future 
research. 
 
The alternative macrophage phenotype triggers resolution of inflammation and promotes wound 
healing [44–46]. Thus, one could speculate that defective activation of healing processes may be 
involved in the more severe inflammatory responses found in MKP-1 deficient animals in 
experimental models such as arthritis, inflammatory bone loss and sepsis [31,41,47]. The present 
results are also supported by the findings that muscle healing is impaired in MKP-1-deficient animals 
[48], and that MKP-1 is expressed at high levels in healing skin wounds [49]. This implies that during 
infection / inflammation, MKP-1 may serve as a factor maintaining balance between the acute 
inflammatory response and later wound healing / tissue repair processes.  
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MKP-1 expression is increased by glucocorticoids [33,50], which was also seen in the present study, 
and MKP-1 has been shown to mediate some of the anti-inflammatory effects of these compounds in 
macrophages and other cells exposed to proinflammatory stimuli [32,34]. In the present study, LPS-
induced IL-6 and iNOS expression was downregulated by dexamethasone in peritoneal macrophages 
from wild-type animals, but this effect was impaired in macrophages from MKP-1 deficient mice, 
and these results are in line with the published data [29,51]. Dexamethasone was also found to 
increase the levels of markers of inflammation-resolving M(IL-4/IL-13) phenotype as shown 
previously [52,53]. Notably, the expression of M(IL-4/IL-13) markers induced by dexamethasone 
was impaired in macrophages from MKP-1 deficient mice as compared to those from wild-type 
animals. These data suggest that the dexamethasone-induced healing-promoting M(IL-4/IL-13) 
macrophage activation is at least partly mediated by MKP-1, which is a novel finding. Together these 
results suggest that MKP-1 is a central endogenous mediator of the anti-inflammatory effects of 
glucocorticoids, both by suppressing proinflammatory macrophage phenotypes and by shifting 
macrophage activation towards anti-inflammatory and healing-promoting phenotypes. These data 
support the importance of MKP-1 as an anti-inflammatory drug target, together with the earlier 
findings showing that the effects of compounds such as the anti-rheumatic drug aurothiomalate, PDE4 
inhibitor rolipram, β2 receptor agonist salbutamol and vitamin D are at least partly mediated by  
MKP-1 [35,36,54,55]. 
 
In conclusion, we found that the expression of M(LPS) markers (iNOS and IL-6) was suppressed by 
MKP-1, while the expression of M(IL-4/IL-13) markers (arginase 1, Ym-1 and FGF2) induced by the 
respective cytokines was enhanced by MKP-1. This suggests that MKP-1 limits the magnitude of the 
acute inflammatory response and stimulates the onset of tissue repair processes following 
inflammation and tissue injury. Furthermore, MKP-1 seems to be an important factor mediating the 
anti-inflammatory actions of glucocorticoids via two mechanisms: by suppressing proinflammatory 
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macrophage activation and by promoting the anti-inflammatory macrophage phenotypes that mediate 
healing processes. 
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Figures 
 
 
 
Figure 1: LPS and combination of IL-4 and IL-13 enhanced the expression of markers of the 
classical M(LPS) and alternative M(IL-4/IL-13) macrophage phenotypes. J774 macrophages 
were cultured with LPS (10 ng/ml) (A and B) or a combination of IL-4 and IL-13 (both 10 ng/ml)  
(C-D) for 0.5 – 24 h to induce the respective phenotypes. mRNA levels of the M(LPS) markers IL-6 
(A) and inducible nitric oxide synthase (iNOS) (B), as well as M(IL-4/IL-13) markers arginase 1 (C) 
and Ym-1 (D) were measured with quantitative RT-PCR and their expression levels were normalized 
against GAPDH. The values were compared to the untreated control (0 h) which was set as 1. The 
results are expressed as mean ± SEM, n = 4. **: p < 0.01 and *: p < 0.05, compared to the 0 h time 
point. 
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Figure 2. MKP-1 deficiency increased the expression of markers of classical M(LPS) phenotype 
and decreased the expression of markers of alternative M(IL-4/IL-13) phenotype in murine 
macrophages. Peritoneal macrophages from wild-type (WT) and MKP-1 deficient (knock-out, KO) 
mice were cultured with either LPS (100 ng/ml) for 4 h (A-B), or with a combination of IL-4 and  
IL-13 (both 10 ng/ml) for 24 h (C-E). mRNA levels of the M(LPS) markers IL-6 (A) and inducible 
nitric oxide synthase (iNOS) (B), and M(IL-4/IL-13) markers arginase 1 (C), Ym-1 (D) and fibroblast 
growth factor 2 (FGF2) (E) were measured with quantitative RT-PCR and their expression levels 
were normalized against GAPDH. All values were compared to the WT control, which was set as 1. 
The results are expressed as mean + SEM, cells from six WT and six KO mice were pooled to give n 
= 4. **: p < 0.01, compared to the untreated control; #: p < 0.05, ##: p < 0.01 and ns: not significant 
(p > 0.05), compared to the indicated sample. The experiments were repeated three times with similar 
results. 
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Figure 3: Dexamethasone decreased the expression of markers of proinflammatory M(LPS) 
activation in J774 macrophages. J774 cells were cultured with LPS (10 ng/ml) for 4 hours (A and 
C) or for 24 h (B and D), with or without dexamethasone (1 µM). IL-6 (A) and inducible nitric oxide 
(iNOS) (C) mRNA levels were measured with quantitative RT-PCR and their expression levels were 
normalized against GAPDH. The results were compared against cells treated with LPS alone, which 
was set as 100 %. IL-6 protein levels were determined with ELISA (B), and NO production was 
assessed by measuring the concentration of its stable metabolite nitrite by Griess method (D). The 
results are expressed as mean + SEM, n = 4. In B, LPS alone raised the IL-6 concentration to 2.8±0.2 
ng/ml, and addition of dexamethasone reduced it to 0.3±0.01 ng/ml. In D, LPS alone raised nitrate 
concentration to 18.6±0.04 µM, and dexamethasone reduced it to 0.9±0.03 µM. **: p < 0.01, 
compared to the untreated control; #: p < 0.05, ##: p < 0.01 and ns: not significant (p > 0.05), 
compared to the indicated sample. 
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Figure 4: Dexamethasone increased the expression of markers of the anti-inflammatory and 
healing-promoting M(IL-4/IL-13) activation in J774 macrophages. J774 macrophages were 
cultured with a combination of IL- 4 and IL-13 (both 10 ng/ml) for 24 h, with or without 
dexamethasone (1 µM). Arginase 1 (A) and Ym-1 (C) mRNA levels were measured with quantitative 
RT-PCR and their expression levels were normalized against GAPDH. Arginase 1 protein levels were 
determined with Western blotting (B). All values were compared to the sample treated with IL-4 and 
IL-13 alone, which was set as 100 %. The results are expressed as mean + SEM, n = 4. **: p < 0.01, 
compared to the untreated control; #: p < 0.05, ##: p < 0.01 and ns: not significant (p > 0.05), 
compared to the indicated sample. In (B), shown is also a representative Western blotting gel of four 
with similar results.  
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Figure 5. Dexamethasone decreased markers of M(LPS) activation and increased those of 
M(IL-4/IL-13) activation in macrophages from wild-type mice, and both effects were 
attenuated in macrophages from MKP-1 deficient mice. Peritoneal macrophages from wild-type 
(WT) and MKP-1 deficient (knock-out, KO) mice were cultured with either LPS (100 ng/ml) for 4 h 
(A and B) or with a combination of IL-4 and IL-13 (both 10 ng/ml) for 24 h (C-E), in the absence or 
presence of dexamethasone (1 µM). mRNA levels of the M(LPS) markers IL-6 (A) and inducible 
nitric oxide synthase (iNOS) (B), and the M(IL-4/IL-13) markers arginase 1 (C), Ym-1 (D) and 
fibroblast growth factor 2 (FGF2) (E) were measured with quantitative RT-PCR and their expression 
levels were normalized against GAPDH. WT and KO values were compared separately to the 
respective samples without dexamethasone, which were set as 100 %. The results are expressed as 
mean + SEM, cells from six WT and six KO mice were pooled to give n = 4. **: p < 0.01, compared 
to the control treated with LPS or IL-4 + IL-13 alone; #: p < 0.05 and ##: p < 0.01, compared to the 
indicated sample. The experiments were repeated two times with similar results. 
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Figure 6. MKP-1 expression was increased by dexamethasone in classically activated M(LPS) 
and alternatively activated M(IL-4/IL-13) macrophages. (A): Peritoneal macrophages from wild-
type mice were incubated for 1 h with dexamethasone (1 µM), with LPS (10 ng/ml), with IL-4 and 
IL-13 (10 ng/ml) or with their combinations as indicated, and MKP-1 mRNA was detected by 
quantitative RT-PCR. (B and C): J774 macrophages were incubated for 0.5 – 24 h with 
dexamethasone (1 uM), with LPS (10 ng/ml), with IL-4 and IL-13 (both 10 ng/ml) or with their 
combinations as indicated. MKP-1 mRNA was detected by quantitative RT-PCR and its expression 
levels were normalized against GAPDH. (B) shows the time-response curves and (C) indicates total 
area under the curves of (B), estimated by trapezoidal integration. (D): J774 macrophages were 
incubated for 1 h as described in (A), and MKP-1 protein levels were determined with Western 
blotting and actin was used as a loading control. The results are expressed as mean + SEM, n = 4.  
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**: p < 0.01 and*: p < 0.05, compared to the control, ##: p < 0.01 for indicated comparisons. In (D), 
shown is also a representative Western blotting gel of four with similar results. 
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Tables 
 
Table 1: Primers and probes used for quantitative RT-PCR 
Primer/probe Sequence 
mIL-6 forward 5′-TCGGAGGCTTAATTACACATGTTC-3′ 
mIL-6 reverse 5′-CAAGTGCATCATCGTTGTTCATAC-3′ 
mIL-6 probe 5′-Fam-CAGAATTGCCATTGCACAACTCTTTTCTCA-TAMRA-3′ 
miNOS forward 5′-CCTGGTACGGGCATTGCT-3′ 
miNOS reverse 5′-GCTCATGCGGCCTCCTT-3′ 
miNOS probe 5′-Fam-CAGCAGCGGCTCCATGACTCCC-TAMRA-3′ 
mMKP-1 forward 5′-CTCCTGGTTCAACGAGGCTATT-3′ 
mMKP-1 reverse 5′-TGCCGGCCTGGCAAT-3′ 
mMKP-1 probe 5′-Fam-CCATCAAGGATGCTGGAGGGAGAGTGTT-TAMRA-3′ 
mARG1 forward 5′-TCCAAGCCAAAGTCCTTAGAGATTAT-3′ 
mARG1 reverse 5′-CGTCATACTCTGTTTCTTTAAGTTTTTCC-3′ 
mARG1 probe 5′-Fam-CGCCTTTCTCAAAAGGACAGCCTCGA-TAMRA-3′ 
mYm-1 forward 5′-AGTGGGTTGGTTATGACAATGTCA-3′ 
mYm-1 reverse 5′-GACCACGGCACCTCCTAAATT-3′ 
mYm-1 probe 5′- Fam-AGCTTCAAGTTGAAGGCTCAGTGGCTCA-TAMRA-3′ 
mGAPDH forward 5′-GCATGGCCTTCCGTGTTC-3′ 
mGAPDH reverse 5′-GATGTCATCATACTTGGCAGGTTT-3′ 
mGAPDH probe 5′-Fam-TCGTGGATCTGACGTGCCGCC-TAMRA-3′ 
 
 
 
